This report, complemented by data from previous cases, strongly suggests shared pathways between JAK2 activation and oncogenic events resulting in ALL, CML and probably additional lympho- and myeloproliferative disorders. The gene discussed is JAK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.